---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-25-000004"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T23:10:40.957301+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biogen Q4 revenue up 3% to $2.5B, non-GAAP EPS $3.44; FY2025 guidance calls for revenue decline

## Summary
- Q4 total revenue $2.5B (+3% YoY); GAAP EPS $1.83, non-GAAP EPS $3.44 (+17% YoY).
- Full year 2024 revenue $9.7B (-2% YoY); non-GAAP EPS $16.47 (+12% YoY).
- LEQEMBI global in-market sales ~$87M; SKYCLARYS revenue ~$102M, patient count nearly doubled vs end 2023.
- Regulatory milestones: LEQEMBI subcutaneous BLA accepted (PDUFA Aug 31, 2025); nusinersen higher dose filings accepted (PDUFA Sep 22, 2025).
- FY2025 guidance: non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit % at constant currency.

## SEC filing metadata
- accession: 0000875045-25-000004
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/0000875045-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/biib-20250212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-25-000004
- JSON: https://secwatch.observer/filing/0000875045-25-000004.json
- Plain text: https://secwatch.observer/filing/0000875045-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.